Topic: How To Invest

Hi Pat! I would like your opinion on Omeros Corporation. This small biotech/pharma company just reported positive results from their Phase III clinical trial on a compound used in lens replacement. Thanks.

Article Excerpt

Omeros Corp., $8.85, symbol OMER on Nasdaq (Shares outstanding: 22.4 million; Market cap: $198.2 million; www.omeros.com), is a pharmaceutical company that’s developing new drugs for treating problems that patients can develop while undergoing surgery. Omeros’ PharmacoSurgery drug therapies aim to treat post-operative symptoms like inflammation and pain before they occur. At the same time, these drugs are designed to not to interfere with the body’s response to combating infections. The company is working towards undertaking a Phase III trial on OMS103HP, a variation of its drug for patients undergoing arthroscopic surgery. This treatment has completed Phase II testing. However, Omeros’ most promising drug is OMS302, for patients undergoing lens replacement surgery. This drug, which is a liquid that surgeons apply to the eye, received positive results in a 405-patient Phase III trial in the U.S. The trial showed that OMS302 kept pupils dilated better than a placebo. Sustained pupil dilation is important for lens replacement surgery. If the pupil shrinks during the procedure, it…